Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US

Subramanian Venkatesan, Martine Lamfers, Sieger Leenstra, Arnold G. Vulto*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

Kinase inhibitors form the largest class of novel anticancer drugs. To date, more than 20 kinase inhibitors have been approved for clinical use. Lengthy patent rights keep the cost of these new anticancer drugs high. In order to anticipate the introduction of generics we have reviewed the patent expiry and the indications of kinase inhibitors approved for use in Europe and the US. Most of these drugs are currently used in the treatment of several types of leukaemia and their patent protection will only expire after more than a decade.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalGaBI Journal
Volume6
Issue number2
DOIs
Publication statusPublished - 15 Mar 2017

Bibliographical note

Publisher Copyright:
© 2017 Pro Pharma Communications International.

Fingerprint

Dive into the research topics of 'Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and the US'. Together they form a unique fingerprint.

Cite this